February 28, 2017 / 9:42 PM / 5 months ago

BRIEF-Dermira reports qtrly loss per share $0.21

1 Min Read

Feb 28 (Reuters) - Dermira Inc

* Planned submission of NDA for Glycopyrronium Tosylate (formerly DRM04) in 2h17 on schedule after pre-NDA meeting with FDA

* Estimates collaboration and license revenue for 2017 of approximately $4.3 million

* Dermira inc qtrly loss per share $0.21

* Estimates operating expenses for 2017 of $165.0 - $175.0 million

* Expects a balance of over $145.0 million in cash and investments at december 31, 2017

* Dermira reports fourth quarter and full year 2016 financial results and provides corporate update

* Q4 revenue $22.5 million

* Q4 revenue view $293,000 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below